Site navigation

Navigation

Osteosarcoma - mifamurtide

Mifamurtide for the treatment of osteosarcoma

Status: In progress
Expected date of issue: TBC
Wave: 17
Process: STA
Topic area:
  • Cancer
 

NICE project team

Executive Lead: Gillian Leng
Technical Lead: Fay McCracken & Nicola Hay
Communications manager: Sarita Tamber
Project manager: Bijal Chandarana
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 23 October 2008
1st appraisal committee meeting: 18 February 2009
Top


 

Stakeholders

Consultees Commentators (no right to submit or appeal)
Manufacturers / Sponsors General
  • IDM Pharma (mifamurtide)

Patient / Carer Groups

  • Action for Sick Children
  • Adam Dealey Foundation for Ewing Sarcoma
  • Afiya Trust
  • Age Concern England
  • Anthony Pilcher Bone Cancer Trust
  • Association for Children with Life Threatening or Terminal Conditions
  • Black Health Agency
  • Bone Cancer Research Trust
  • British Ethnic Health Awareness Foundation
  • CANCERactive
  • Cancer Black Care
  • Cancer Equality
  • Cancer Voices
  • Cancerbackup
  • Children's Society
  • Chinese National Healthy Living Centre
  • CLIC Sargent
  • Confederation of Indian Organisations
  • Counsel and Care
  • Equalities National Council
  • Help Adolescents with Cancer
  • Help the Aged
  • Leonard Cheshire Disability
  • Limbless Association
  • Limb Loss Information Centre
  • Macmillan Cancer Support
  • Maggie's Centres
  • Marie Curie Cancer Care
  • Muslim Council of Great Britain
  • Muslim Health Network
  • National Alliance of Childhood Cancer Patient Organisations
  • National Association for the Relief of Paget's Disease
  • National Cancer Alliance
  • National Children's Bureau
  • National Council for Palliative Care
  • NCH – The Children's Charity
  • RADAR - Royal Association for Disability & Rehabilitation
  • Rarer Cancers Forum
  • Sarcoma UK
  • Skill: National Bureau for Students with Disabilities
  • South Asian Health Foundation
  • Specialised Healthcare Alliance
  • Steps
  • Sue Ryder Care
  • Teenage Cancer Trust
  • Tenovus Cancer Information Centre
  • WellChild

Professional Groups

  • Association of Cancer Physicians
  • Association of Surgeons of Great Britain and Ireland
  • British Association for Services to the Elderly
  • British Association of Surgical Oncology
  • British Institute of Musculoskeletal Medicine
  • British Oncological Association
  • British Orthopaedic Association
  • British Orthopaedic Oncology Society
  • British Psychosocial Oncology Society
  • British Sarcoma Group
  • British Society of Rehabilitation Medicine
  • Cancer Networks Pharmacists Forum
  • Cancer Research UK
  • Children's Cancer and Leukaemia Group
  • Royal College of Anaesthetists
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Paediatric and Child Health
  • Royal College of Pathologists
  • Royal College of Physicians, Medical Oncology Joint Special Committee
  • Royal College of Radiologists
  • Royal College of Surgeons
  • Royal Pharmaceutical Society
  • Royal Society of Medicine – Intellectual Disabilities Forum
  • United Kingdom Clinical Pharmacy Association
  • United Kingdom Oncology Nursing Society
  • Vascular Society

Others

  • Department of Health
  • Sheffield PCT
  • Welsh Assembly Government
  • West Sussex Teaching PCT
  • Age Concern Cymru
  • Board of Community Health Councils in Wales
  • British National Formulary
  • Cancer Care Cymru
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency
  • National Association of Primary Care
  • National Public Health Service for Wales
  • NHS Alliance
  • NHS Confederation
  • NHS Purchasing and Supply Agency
  • NHS Quality Improvement Scotland
  • Scottish Medicines Consortium

Comparator manufacturer(s)

  • Baxter Healthcare (ifosfamide)
  • Cephalon UK (doxorubicin)
  • Goldshield Pharmaceuticals  (methotrexate)
  • Hospira UK (cisplatin, doxorubicin, methotrexate)
  • Medac (doxorubicin)
  • Pfizer (cisplatin, doxorubicin)
  • Teva UK (cisplatin, methotrexate)
  • Wockhardt UK (cisplatin, doxorubicin, methotrexate)
  • Wyeth Pharmaceuticals (methotrexateGilead Sciences (adefovir dipivoxil)

Relevant research groups

  • Bone Research Society
  • Christopher Hardman Osteosarcoma Research Fund
  • Institute of Cancer Research
  • MRC Clinical Trials Unit
  • National Cancer Research Institute
  • National Cancer Research Network
  • Policy Research Institute on Ageing and Ethnicity
  • Research Institute for the Care of Older People

Evidence Review Group

  • National Coordinating Centre for Health Technology Assessment
  • School of Health & Related Research Sheffield (ScHARR)

Associated Guideline Groups

  • National Collaborating Centre for Cancer
  • National Collaborating Centre for Women and Children's Health

Associated Public Health Groups

  • None

National organisations wishing to register as a stakeholder can do so via the link below.
Top


 

Project history

Date Update
6 May 2009

Mifamurtide has now received a centralised marketing authorisation from the European Commission for the treatment of osteosarcoma.  

Please note that the date this drug will be launched in the UK has not been finalised and the final price of the drug has not been formally announced by the manufacturer. Therefore, we cannot release the decision agreed by the Committee and the evidence documentation related to the appraisal at this time.

This appraisal continues to be temporarily on hold, and the website will be updated once further information is available.
5 March 2009 Mifamurtidehas not received a centralised marketing authorisation from the European Commission and therefore we are unable to circulate the Appraisal Consultation Document (ACD) for consultation. As a result we have also cancelled the Appraisal Committee Meeting scheduled for 22 April 2009. This appraisal is temporarily on hold, and the website will be updated once further information is available.
Top


 

Key documents

This page was last updated:   06 May 2009